Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zejula (niraparib) for the Treatment of Ovarian Cancer

Drug (Brand / Generic)

Zejula™ / Niraparib

Developer

Tesaro

Therapy Class

Poly ADP-ribose polymerase (PARP) inhibitor

Current Indication

Ovarian, fallopian tube, or primary peritoneal cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top